2021results about How to "Promote activation" patented technology

Systems, program product, apparatus and method for transmitting and processing the sale of a transaction card product over an existing payment network using partial authorization messaging, are provided. An example of such a system can include a merchant POS apparatus equipped to support partial authorization messaging, a transaction card issuer server in communication therewith, and a transaction card product. The transaction card product can include a conventional transaction card securely wrapped within a tamper evident container that can carry its own magnetic strip. The container magnetic strip can store an assigned unique card identifier linked to, but different from, the card identifier normally associated with the card. The container card identifier stored in the container magnetic strip is compatible with the merchant POS card reader and is usable to activate the card without the merchant or consumer having access to the card, the card identifier, or the card magnetic strip.

A system and method for cash based purchasing using electronic commerce channels such as mobile telephone networks. Customers use cash to purchase goods and services by using a vendor's point of sale device such as a mobile telephone. A server side mobile wallet provides secure storage of user identity and profiles and a payment mechanism for users to obtain goods and services from a point of sale device. Service providers or suppliers pay a commission to point of sale vendors for use of the vendor's account and point of sale device to perform transactions for customers. A platform is provided for establishment and use of hierarchal vendor network over a number of different mobile channels.

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

A system and method is provided for an injectable substance delivery pen comprising a microneedle hub assembly removably engaged with a pen device body which includes a cartridge, a plunger, and a drive mechanism. The hub assembly includes at least one microneedle for intradermal or shallow subcutaneous injection of the contents of the cartridge. The cartridge, plunger and drive mechanism components of the pen body are fabricated of non-compliant and non-compressible materials to allow effective communication of the cartridge contents via the microneedle patient interface.

An improved hearing aid, and processes for adaptively processing signals therein to improve the perception of desired sounds by a user thereof. In one broad aspect, the present invention relates to a process in which one or more signal processing methods are applied to frequency band signals derived from an input digital signal. The level of each frequency band signal is computed and compared to at least one plurality of threshold values to determine which signal processing schemes are to be applied. In one embodiment of the invention, each plurality of threshold values to which levels of the frequency band signals are compared, is derived from a speech-shaped spectrum. Additional measures such as amplitude modulation or a signal index may also be employed and compared to corresponding threshold values in the determination.

It has been discovered that the stimulation of beta -adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta -adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta -adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta -adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

A therapeutic dispenser is provided that includes a housing and a carriage movably supported by the housing and including an engagement surface at a distal end thereof. A plunger is supported by the carriage and engageable with the housing to dispense a first therapeutic through the engagement surface. A second therapeutic is supported with the housing. The first therapeutic and the second therapeutic are individually dispensable from the housing. The housing may include a channel that guides movement of the carriage. The housing can include a handle and a cap. The cap is releasably engageable with the handle.

A method for measuring the conduction velocity of a depolarization wave in a tissue employs a first satellite located within the tissue and a second that satellite is located within the tissue a distance away from the first satellite, e.g., by using the time of depolarization wave as reported from each satellite and the distance to determine velocity of the wave. Also provided are systems and kits that find use in accordance with the invention.

An insect and / or arthropod trapping device that generates its own attractants of carbon dioxide (CO2), and ammonia through the chemical reaction of adding a weakly acidic liquid such as vinegar (acetic acid) to solids such as baking soda (sodium bicarbonate), with the optional addition of urea and / or lactic acid. The liquids are mixed over a period of days onto the solids to generate CO2 in the vicinity of an insect / arthropod trap having glue boards that trap the insects and arthropods when they alight on the glue board. The attractants can be used with devices that utilize various combinations of other insect attractants and traps such as sound, light, scent, visual, electrical, chemical, sticky surfaces, mesh nets, etc., to further attract and trap or kill insects and / or arthropods.

Pharmaceutical compositions and methods for using are provided for restoring β-cell mass and function in a mammal in need thereof. The pharmaceutical compositions have a biological response modifier and a β-cell growth factor in admixture with a pharmaceutically acceptable carrier, adjuvant or vehicle.

The invention relates to an improver for saline-alkali soil. The improver comprises a powder agent and a water agent, wherein the powder agent comprises the following components: organic matters, plant mycelium protein powder, active calcium, calcium superphosphate, aluminum sulfate, fatty alcohol polyoxyethylene ether ammonium sulfate, amino acid powder, bacillus subtilis and photosynthetic bacteria, and the water agent comprises the following components: citric acid, fulvic acid, humic acid, malic acid, maleic acid, fumaric acid, L-tartaric acid, pyrophosphoric acid, humic acid, lactic acid, oxalic acid, salicylic acid, sodium ion adsorbent, Tween-80 and water. The improver disclosed by the invention can improve the soil from multiple angles, namely soil structure, microorganism species, a chemical method and the like, obviously promote the release of iron and phosphorus in the soil, improve the soil structure, effectively reduce the content of sodium ions in the soil, reduce the pH value of the soil and restore land to a normal planting state after being used continuously for two years.

The invention discloses a magnesium-based composite hydrogen storage material comprising the following compositions by weight percent: 1.0-10.0% of Al, 1.0-5.0% of Ni, and the balance of Mg. A preparation method thereof comprising the following steps: at first, smelting block-shaped metal Mg and Al by a medium frequency induction to prepare Mg17Al12 alloy which is crushed to 300 meshes; hydrogenising Mg powder at 340 DEG C under a hydrogen atmosphere of 4.0MPa to prepare MgH2; then blending Mg17Al12, MgH2, Ni powder in accordance with contents by weight percent for ball-grinding for 60 to 100 hours under an atmosphere of argon. The magnesium-based composite hydrogen storage material can reversely absorb and release hydrogen at low temperature, and has high hydrogen storage capacity, excellent activation performance and superior hydrogen absorbing and releasing kinetics property. The magnesium-based composite hydrogen storage material can be used for manufacturing hydrogen source to facilitate purification and storage and transportation of hydrogen, and can also used for hydrogen storage material for fuel cells.

A safety sensing and / or release system for a closed compartment of a vehicle is operable to detect an occupant within the vehicle compartment. The system may be operable to sense ambient conditions in the vehicle compartment, and may generate a control signal in response to the sensed conditions. The system may actuate indicators to notify operators of the vehicle that there is a person or animal detected in the compartment. Optionally, the system may open the vehicle compartment in response to a detection of an occupant and the sensed conditions. The safety system includes a false trigger protection means that limits or reduces false detections of a person or animal within the compartment.

A system and method for cardiac resynchronization therapy in which pacing control parameters are automatically adjusted by comparison of local electrograms acquired by a cardiac implantable electrical device with a model of cardiac electrical activity derived from surface-lead electrocardiograph measurements under baseline and paced conditions is provided. The adjusted pacing control parameters guarantee substantially maximum evidence of ventricular activation wavefront fusion while reducing the risk of compromising diastolic function. Atrioventricular intervals (AVIs] are measured and utilized to constrain the adjustment of pacing control parameters such that diastolic dysfunctions are not induced in the patient's heart.

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules consisting of a tumor targeting moiety fused with one or more costimulatory molecules / chemokines / cytokines.

It has been discovered that the stimulation of beta-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising beta-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by beta-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E2 (PG E2), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of beta-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E2, or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium / calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.